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Summary
Background Use of heterologous prime-boost COVID-19 vaccine schedules could facilitate mass COVID-19 
immunisation. However, we have previously reported that heterologous schedules incorporating an adenoviral 
vectored vaccine (ChAdOx1 nCoV-19, AstraZeneca; hereafter referred to as ChAd) and an mRNA vaccine (BNT162b2, 
Pfizer–BioNTech; hereafter referred to as BNT) at a 4-week interval are more reactogenic than homologous schedules. 
Here, we report the safety and immunogenicity of heterologous schedules with the ChAd and BNT vaccines.
Methods Com-COV is a participant-blinded, randomised, non-inferiority trial evaluating vaccine safety, reactogenicity, 
and immunogenicity. Adults aged 50 years and older with no or well controlled comorbidities and no previous 
SARS-CoV-2 infection by laboratory confirmation were eligible and were recruited at eight sites across the UK. The 
majority of eligible participants were enrolled into the general cohort (28-day or 84-day prime-boost intervals), who 
were randomly assigned (1:1:1:1:1:1:1:1) to receive ChAd/ChAd, ChAd/BNT, BNT/BNT, or BNT/ChAd, administered 
at either 28-day or 84-day prime-boost intervals. A small subset of eligible participants (n=100) were enrolled into an 
immunology cohort, who had additional blood tests to evaluate immune responses; these participants were randomly 
assigned (1:1:1:1) to the four schedules (28-day interval only). Participants were masked to the vaccine received but 
not to the prime-boost interval. The primary endpoint was the geometric mean ratio (GMR) of serum SARS-CoV-2 
anti-spike IgG concentration (measured by ELISA) at 28 days after boost, when comparing ChAd/BNT with ChAd/ChAd, 
and BNT/ChAd with BNT/BNT. The heterologous schedules were considered non-inferior to the approved 
homologous schedules if the lower limit of the one-sided 97·5% CI of the GMR of these comparisons was greater 
than 0·63. The primary analysis was done in the per-protocol population, who were seronegative at baseline. Safety 
analyses were done among participants receiving at least one dose of a study vaccine. The trial is registered with 
ISRCTN, 69254139.
Findings Between Feb 11 and Feb 26, 2021, 830 participants were enrolled and randomised, including 
463 participants with a 28-day prime-boost interval, for whom results are reported here. The mean age of 
participants was 57·8 years (SD 4·7), with 212 (46%) female participants and 117 (25%) from ethnic minorities. 
At day 28 post boost, the geometric mean concentration of SARS-CoV-2 anti-spike IgG in ChAd/BNT recipients 
(12 906 ELU/mL) was non-inferior to that in ChAd/ChAd recipients (1392 ELU/mL), with a GMR of 9·2 
(one-sided 97·5% CI 7·5 to ∞). In participants primed with BNT, we did not show non-inferiority of the 
heterologous schedule (BNT/ChAd, 7133 ELU/mL) against the homologous schedule (BNT/BNT, 14 080 ELU/mL), 
with a GMR of 0·51 (one-sided 97·5% CI 0·43 to ∞). Four serious adverse events occurred across all groups, none 
of which were considered to be related to immunisation.
Interpretation Despite the BNT/ChAd regimen not meeting non-inferiority criteria, the SARS-CoV-2 anti-spike IgG 
concentrations of both heterologous schedules were higher than that of a licensed vaccine schedule (ChAd/ChAd) 
with proven efficacy against COVID-19 disease and hospitalisation. Along with the higher immunogenicity of 
ChAd/BNT compared with ChAD/ChAd, these data support flexibility in the use of heterologous prime-boost 
vaccination using ChAd and BNT COVID-19 vaccines.
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Introduction
COVID-19 has severely impacted the world in terms 
of health, society, and economy.1 Immunity through 
vaccination is fundamental to reducing the burden of 
disease, the emergence from current public health 
measures, and the subsequent economic recovery. 
Multiple vaccines with proven effectiveness are being 
deployed globally, including the mRNA vaccine Comirnaty 
(BNT162b2 or tozinameran, Pfizer–BioNTech; hereafter 
referred to as BNT) and the adenoviral vectored vaccine 
Vaxzevria (ChAdOx1 nCoV-19, AstraZeneca; hereafter 
referred to as ChAd), both of which are approved as two-
dose homologous schedules in the UK and elsewhere.2
As of July 30, 2021, more than 3·8 billion COVID-19 
vaccines have been administered worldwide,3 but many 
more people remain unimmunised.4 Heterologous 
vaccine schedules could ease logistical problems inherent 
in some national and international vaccine programmes. 
These schedules could be particularly important in 
low-income and middle-income countries,5 as well as in 
countries that have adopted age-specific restrictions for 
the use of ChAd.6–8
Although the Sputnik V vaccine programme, which 
deploys a heterologous prime-boost schedule using 
Ad26 and Ad5 vectored COVID-19 vaccines, induces a 
robust humoral and cellular response and has shown 
91·6% efficacy against symptomatic disease,9,10 there are 
currently no efficacy data using heterologous schedules 
incorporating COVID-19 vaccines across different 
platforms. Nevertheless, preclinical studies support 
evaluation of this approach,11,12 and results from a 
randomised study in Spain suggested an increase in 
binding and neutralising antibody after boosting 
ChAd-primed participants with BNT, compared with not 
having a boost dose.13 Additionally, early results from an 
observational study in Germany show that humoral 
responses are similar in the cohort receiving BNT/BNT 
at a 3-week interval to those receiving ChAd/BNT at a 
10-week interval, with cellular responses appearing to 
be higher in the ChAd/BNT cohort.14 However, we 
have previously reported that heterologous schedules 
incorporating ChAd and BNT are more reactogenic 
than their homologous schedules.15
Robust data on the safety and immunogenicity of 
heterologous vaccine schedules will help inform the 
use of these schedules in individuals who develop a 
contraindication to a specific vaccine after their first 
dose, and for vaccine programmes looking to mitigate 
Research in context
Evidence before this study
National regulatory authorities have granted emergency use 
authorisations for more than 15 vaccines, among which 
six vaccines have been approved for emergency use by WHO. 
Although more than 3·8 billion COVID-19 vaccines have been 
administered as of July 30, 2021, only approximately 28% of the 
global population has received at least one dose of COVID-19 
vaccine, with approximately 1·1% of the population in low-
income countries having received a vaccine dose. Heterologous 
COVID-19 vaccine schedules have the potential to accelerate 
vaccine roll-out worldwide, especially in low-income and 
middle-income countries. We searched PubMed for research 
articles published between database inception and 
June 22, 2021, using the search terms “(COVID) AND 
(heterologous) AND (vaccin*) NOT (BCG)” with no language 
restrictions. In addition to our previously published 
reactogenicity results, we identified two animal studies using 
combinations of mRNA, adenoviral vectored, inactivated, 
and recombinant protein vaccines as prime-boost schedules. 
Both studies showed robust humoral and cellular responses 
induced by heterologous schedules in mice. In addition, 
we identified two clinical trials on the rAd26 and rAd5 vector-
based heterologous prime-boost schedule (Sputnik V, 
Gamaleya Research Institute of Epidemiology and 
Microbiology), showing good safety profiles, strong humoral or 
cellular responses, and 91·6% vaccine efficacy. Another clinical 
trial, which randomly assigned participants primed with 
ChAdOx1 nCoV-19 (AstraZeneca; ChAd) to receive BNT162b2 
(Pfizer–BioNTech; BNT) as the boost vaccine or no boost 
vaccination, reported a robust immune response and an 
acceptable reactogenicity profile, but with no comparison to a 
homologous vaccine schedule. A further two preprint articles of 
cohort studies evaluating ChAd prime and BNT boost schedules 
showed similar results.
Added value of this study
We report on safety and immunogenicity in the first 
participant-blinded randomised clinical trial using two vaccines 
approved by WHO for emergency use, ChAd and BNT, when 
administered at a 28-day interval in heterologous and 
homologous vaccine schedules (ChAd/ChAd, ChAd/BNT, 
BNT/BNT, and BNT/ChAd). The cellular and humoral responses 
of the two heterologous vaccine schedules at 28 days after the 
boost dose are no lower than those of the ChAd/ChAd schedule, 
which has shown to be highly effective in preventing severe 
COVID-19 disease, and no safety concerns were raised.
Implications of all the available evidence
Now that multiple COVID-19 vaccines have been approved for 
emergency use, the paramount issue in addressing the 
COVID-19 pandemic is to optimise global vaccine coverage 
using the currently available vaccines. The results from our 
study support flexibility in the use of heterologous prime-boost 
schedules with ChAd and BNT, which could accelerate vaccine 
roll-out in some settings. Further studies are needed to 
examine other heterologous schedules, especially those using 
vaccines that are being deployed in low-income and middle-
income countries.
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vaccine supply chain disruption or changes in guidance 
for vaccine usage. In addition, mixed schedules might 
induce an enhanced or more durable humoral or cellular 
immune response compared with licensed schedules, 
and might do so against a greater range of SARS-CoV-2 
variants.
Accordingly, we did a randomised controlled trial to 
determine whether the immune responses to heterologous 
schedules with the ChAd and BNT vaccines are non-
inferior to their equivalent homologous schedules.
Methods
Study design
Com-COV is a participant-blinded, randomised, phase 2, 
UK multicentre, non-inferiority study investigating the 
safety, reactogenicity, and immunogenicity of heterologous 
prime-boost COVID-19 vaccine schedules. Recruitment 
occurred at eight National Health Service and academic 
institutions across the UK. The trial was reviewed and 
approved by the South-Central Berkshire Research Ethics 
Committee (21/SC/0022), the University of Oxford, and the 
Medicines and Healthcare Products Regulatory Agency.
Four permutations of prime-boost schedules using 
the ChAd and BNT vaccines are compared, at two 
different prime-boost intervals (28 days and 84 days) to 
reflect both short and long interval approaches to 
immunisation. The majority of participants were 
enrolled into the general cohort, in which participants 
could be randomly assigned to receive the four vaccine 
schedules at either a 28-day or 84-day interval. A subset 
of participants (n=100, selected on the basis of site 
capacity and participant availability) were enrolled into 
an immunology cohort, in which participants were 
randomly assigned only to vaccine schedules with a 
28-day interval and had four additional blood tests to 
explore the kinetics of the immune responses. Here, 
we report data from all participants who were 
randomly assigned to vaccine schedules with a prime-
boost interval of 28 days. The full protocol is provided in 
the appendix (pp 13–94) and online.16
Participants
COVID-19 vaccine-naive adults aged 50 years and older, 
with no or well controlled mild-to-moderate comorbid-
ities were eligible for recruitment. Key exclusion 
criteria were previous laboratory-confirmed SARS-CoV-2 
infection, history of anaphylaxis, history of allergy to a 
vaccine ingredient, pregnancy, breastfeeding, or intent to 
conceive, and current use of anticoagulants. Full details 
of the inclusion and exclusion criteria can be found in 
the protocol (appendix pp 41–42).
Randomisation and masking
Computer-generated randomisation lists were prepared 
by the study statistician. Participants were block-
randomised (block size four; ratio of 1:1:1:1) within 
the immunology cohort to ChAd/ChAd, ChAd/BNT, 
BNT/BNT, and BNT/ChAd schedules (boost interval 
of 28 days). General cohort participants were block-
randomised (block size eight; ratio of 1:1:1:1:1:1:1:1) to 
ChAd/ChAd, ChAd/BNT, BNT/BNT, and BNT/ChAd 
schedules at boosting intervals of both 28 and 84 days. 
In addition to stratification by cohort, randomisation was 
further stratified by study site. Clinical research nurses 
who were not involved in safety endpoint evaluation did 
the randomisation using REDCap version 10.6.13 and 
prepared and administered the vaccine.
Participants and laboratory staff processing the 
immunogenicity endpoints were masked to the vaccines 
received, but not to the prime-boost interval. Participant 
blinding to vaccines was maintained by concealing 
randomisation pages, preparing vaccines out of sight, 
and applying masking tape to vaccine syringes to conceal 
dose volume and appearance. The clinical team assessing 
the safety endpoints were not masked.
Procedures
Participants who met the inclusion and exclusion criteria 
via the online screening or the telephone screening 
(or both) were invited to the baseline visits (day 0). 
Of these, participants who passed the final eligibility 
assessment and provided written informed consent 
were randomly assigned to a study group.
Two COVID-19 vaccines were used in this study. 
ChAd is a replication-deficient chimpanzee adenovirus 
vectored vaccine, expressing the SARS-CoV-2 spike 
surface glycoprotein with a leading tissue plasminogen 
activator signal sequence. Administration is via 0·5 mL 
intramuscular injection into the upper arm. BNT is 
a lipid nanoparticle-formulated, nucleoside-modified 
mRNA vaccine encoding trimerised SARS-CoV-2 spike 
glycoprotein. Administration is via a 0·3 mL intra-
muscular injection into the upper arm.
Vaccines were administered by appropriately trained 
trial staff at trial sites. Participants were observed for at 
least 15 min after vaccination. During the baseline visit, 
participants were given an oral thermometer, tape 
measure, and diary card (electronic or paper) to record 
solicited, unsolicited, and medically attended adverse 
events with instructions. The study sites’ physicians 
reviewed the diary card regularly to record adverse 
events, adverse events of special interest, and serious 
adverse events. The timepoints for subsequent visits for 
immunogenicity blood sampling are shown in the 
protocol (appendix pp 25–26). During the study visits, 
adverse events, adverse events of special interest, and 
serious adverse events that had not been recorded in the 
diary card were also collected.
Participants who tested positive for SARS-CoV-2 in the 
community were invited for an additional visit for clinical 
assessment, collection of blood samples, and throat 
swab, and completion of a COVID-19 symptom diary.
Serum samples were analysed at Nexelis (Laval, 
Canada) to determine SARS-CoV-2 anti-spike IgG 
For REDCap software see 
https://www.project-redcap.org
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concentrations by ELISA (reported as ELISA laboratory 
units [ELU]/mL) and the 50% neutralising antibody titre 
(NT50) for SARS-CoV-2 pseudotype virus neu tralisation 
assay (PNA), using a vesicular stomatitis virus backbone 
adapted to bear the SARS-CoV-2 spike protein.17 The 
conversion factors to international standard units can 
be found in the appendix (p 12). Sera from day 0 were 
analysed at Porton Down, Public Health England, by 
electrochemiluminescence immunoassay (Cobas plat-
form, Roche Diagnostics) to determine anti-SARS-CoV-2 
nucleocapsid IgG status (reported as negative if 
below a cutoff index of 1·0). Normalised NT50 for 
live SARS-CoV-2 virus (lineage Victoria/01/2020) was 
determined by microneutralisation assay (MNA), also at 
Porton Down, on day 0 and day 56 samples in the ChAd-
primed groups only, due to limited laboratory capacity.17 
IFNγ-secreting T cells specific to whole spike protein 
epitopes designed based on the Wuhan-Hu-1 sequence 
(YP_009724390·1) were detected using a modified 
T-SPOT-Discovery test done at Oxford Immunotec 
(Abingdon, UK) within 32 h of vene puncture, using the 
addition of T-Cell Xtend reagent to extend peripheral 
blood mononuclear cell (PBMC) survival.18 T-cell 
frequencies were reported as spot forming cells (SFC) 
per 250 000 PBMCs with a lower limit of detection 
of one in 250 000 PBMCs, and these results were 
multiplied by four to express frequencies per million 
PBMCs.
Outcomes
The primary outcome was serum SARS-CoV-2 anti-
spike IgG concentration at 28 days after boost for those 
with a prime-boost interval of 28 days, in participants 
who were seronegative for SARS-CoV-2 infection at 
baseline.
Secondary outcomes included reactogenicity, as 
mea sured by solicited local and systemic events for 
7 days after immunisation (reported previously for the 
28-day prime-boost interval groups15) and safety, as 
measured by unsolicited adverse events for 28 days after 
immunisation, medically attended adverse events for 
3 months after immunisation, and adverse events of 
special interest and serious adverse events collected 
throughout the study. Blood biochemistry and 
haematology assessments were measured at baseline 
(day 0), on day of boost and 28 days after boost, with an 
additional day 7 post-boost timepoint (day 35) for the 
immunology cohort only. The detailed definition of 
safety outcomes can be found in the protocol (appendix 
pp 59–64).
Immunological secondary outcomes include SARS-
CoV-2 anti-spike binding IgG concentration, cellular 
responses (measured by IFNγ ELISpot) in peripheral 
blood, and pseudotype virus neutralisation titres at 
days 0, 28, and 56. The immunology cohort had add-
itional visits at days 7, 14, 35, and 42 to explore the kinetics 
of the immune responses further.
Statistical analysis
The sample size was calculated assuming the SD of the 
primary endpoint to be 0·4 at log10 scale and the true 
geometric mean ratio (GMR) between the homologous 
and heterologous group to be one. The study needed to 
recruit 115 participants per group to achieve 90% power 
at a one-sided 2·5% significance level, after adjusting for 
an attrition rate of 25% due to baseline SARS-CoV-2 
seropositivity or loss to follow-up.
The primary analysis of SARS-CoV-2 anti-spike IgG 
was done in participants boosted at day 28 on a per-
protocol basis. The analysis population was participants 
ChAd/ChAd ChAd/BNT BNT/BNT BNT/ChAd
General cohort
Participants, n 90 90 93 90
Age, years
Mean (SD) 58·2 (4·81) 58·0 (4·76) 58·2 (4·85) 57·3 (4·56)
Median (range) 57·6 (50·1–69·1) 57·6 (50·3–68·1) 57·7 (50·2–69·3) 56·1 (50·5–68·9)
Sex
Female 38 (42%) 40 (44%) 49 (53%) 41 (46%)
Male 52 (58%) 50 (56%) 44 (47%) 49 (54%)
Ethnicity
White 70 (78%) 65 (72%) 76 (82%) 66 (73%)
Black 1 (1%) 1 (1%) 0 2 (2%)
Asian 13 (14%) 15 (17%) 7 (8%) 9 (10%)
Mixed 6 (7%) 6 (7%) 8 (9%) 10 (11%)
Other 0 3 (3%) 2 (2%) 3 (3%)
Comorbidities
Cardiovascular 19 (21%) 16 (18%) 18 (19%) 21 (23%)
Respiratory 16 (18%) 11 (12%) 11 (12%) 11 (12%)
Diabetes 7 (8%) 8 (9%) 0 2 (2%)
Immunology cohort
Participants, n 25 24 26 25
Age, years
Mean (SD) 55·7 (4·26) 58·4 (4·60) 56·7 (5·04) 57·6 (4·65)
Median (range) 55·3 (50·7–64·1) 58·9 (51·8–68·3) 54·7 (50·1–67·2) 55·8 (51·4–67·0)
Sex
Female 13 (52%) 9 (38%) 12 (46%) 10 (40%)
Male 12 (48%) 15 (63%) 14 (54%) 15 (60%)
Ethnicity
White 17 (68%) 17 (71%) 17 (65%) 18 (72%)
Black 0 0 2 (8%) 0
Asian 6 (24%) 4 (17%) 4 (15%) 4 (16%)
Mixed 2 (8%) 3 (13%) 2 (8%) 3 (12%)
Other 0 0 1 (4%) 0
Comorbidities
Cardiovascular 7 (28%) 6 (25%) 10 (38%) 7 (28%)
Respiratory 5 (20%) 6 (25%) 6 (23%) 5 (20%)
Diabetes 6 (24%) 1 (4%) 2 (8%) 1 (4%)
Data are n (%) unless otherwise indicated. BNT=BNT162b2 vaccine, Pfizer–BioNTech. ChAd=ChAdOx1 nCoV-19 vaccine, 
AstraZeneca.
Table 1: Baseline characteristics by cohort and vaccine schedule in the 28-day prime-boost interval study 
groups
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who were seronegative for SARS-CoV-2 at baseline 
(defined by anti-nucleocapsid IgG negativity at day 0 
and no confirmed SARS-CoV-2 infection within 14 days 
after prime vaccination), whose primary endpoint data 
were available, and who had no protocol deviations. 
The GMR was calculated as the antilogarithm of the 
difference between the mean of the log10 transformed 
SARS-CoV-2 anti-spike IgG in the heterologous group 
and that in the homologous group (as the reference), 
after adjusting for study site and cohort (immunology 
or general) as randomisation design variables in the 
linear regression model. The GMRs were reported 
separately for par ticipants primed with ChAd and those 
with BNT, with a one-sided 97·5% CI to adjust for 
multiple testing because two primary comparisons 
were made. The criterion for non-inferiority of 
Figure 1: Trial profile
BNT=BNT162b2 vaccine, Pfizer–BioNTech. ChAd=ChAdOx1 nCoV-19 vaccine, AstraZeneca.
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heterologous boost compared with homologous boost 
was for the lower limit of the one-sided 97·5% CI of the 
GMR to be greater than 0·63; this cutoff was chosen on 
a pragmatic basis to approach the WHO criterion of 
0·67 for licensing new vaccines when using GMR as 
the primary endpoint, while still allowing rapid study 
delivery.19
According to recommended practice for non-inferiority 
trials,20 we also present the two-sided 95% CI of the 
adjusted GMRs among the modified intention-to-treat 
population, which followed the per-protocol population 
definition but included participants whose visit timelines 
fell outside protocol windows, to allow a conservative 
estimation for superiority comparison, as secondary 
analyses. The heterologous group was considered 
superior to the homologous group if the lower limit of 
the two-sided 95% CI was greater than one, and the 
homologous group was considered superior to the 
heterologous group if the upper limit of the two-sided 
95% CI was less than one. The geometric means of 
secondary immunological outcomes were reported in the 
modified intention-to-treat population. The proportions 
of participants with responses higher than the lower 
limit of detection or higher than the lower limit of 
quantification were calculated by vaccine schedule, with 
95% CIs calculated by the binomial exact method for 
each secondary immunological outcome, and compared 
between heterologous and homologous groups using 
Fisher’s exact test. Censored data reported to be below 
the lower limit of detection or lower limit of quantification 
were imputed with a value equal to half of the threshold 
before transformation. Between-schedule comparisons 
of immunological outcomes were evaluated by linear 
regression models adjusting for study site and cohort as 
secondary analyses. If a normal distribution could not 
be rendered after transformation, the Mann-Whitney 
U test was used. Correlations between different immu-
nological outcomes were evaluated by Pearson correlation 
coefficients.
As an exploratory analysis, subgroup analyses were 
done for primary and secondary immunogenicity 
outcomes by age (50–59 years and ≥60 years), sex (male 
and female) and baseline comorbidity (presence or 
absence of cardiovascular disease, respiratory disease, or 
diabetes). p values for interaction were reported using 
the Wald test, and the significance level for interaction 
was set to be two-sided 0·0024 using Bonferroni 
correction.
Participants who received at least one dose of a study 
vaccine were included in the safety analysis. The 
proportion of participants with at least one safety event 
was reported by vaccine schedule. Fisher’s exact test 
was used to compare the difference between schedules. 
All statistical analyses were done using R version 3.6.2.
An independent data safety monitoring board reviewed 
safety data, and local trial-site physicians provided 
Prime with ChAd Prime with BNT
ChAd/ChAd ChAd/BNT GMR* BNT/BNT BNT/ChAd GMR*
Per-protocol analysis
N 104 104 ·· 109 109 ··





(11 404 to 14 604)
9·2 
(97·5% CI 7·5 to ∞)
14 080 




(97·5% CI 0·43 to ∞)
Modified intention-to-treat analysis
N 105 108 ·· 110 109 ··
SARS-CoV-2 anti-spike IgG
n 105 108 ·· 110 109 ··
Concentration, ELU/mL 1387 
(1186 to 1623)
12 995 
(11 520 to 14 660)
9·3 
(95% CI 7·7 to 11·4)
13 938 




(95% CI 0·44 to 0·60)
Live virus neutralising antibody
n 98 104 ·· ·· ·· ··
Normalised NT50 201 (171 to 235) 1269 (1107 to 1454) 6·4 (95% CI 5·2 to 7·8) ·· ·· ··
Pseudotype virus neutralising antibody












(95% CI 0·51 to 0·88)
Cellular response
n 104 108 ·· 110 109 ··
SFC per million PBMCs 48 (37 to 61) 184 (152 to 223) 3·9 (95% CI 2·9 to 5·3) 80 (63 to 101) 97 (76 to 125) 1·2 (95% CI 0·87 to 1·7)
Data shown are geometric mean (95% CI) for continuous variables. ChAd=ChAdOx1 nCoV-19 vaccine, AstraZeneca. BNT=BNT162b2 vaccine, Pfizer–BioNTech. GMR=geometric mean ratio. ELU=ELISA laboratory 
units. NT50=50% neutralising antibody titre. SFC=spot-forming units. PBMC=peripheral blood mononuclear cell. *GMRs were adjusted for randomisation stratification variables, including study site and cohort, 
with one-sided 97·5% CIs in per-protocol analyses and two-sided 95% CIs in the modified intention-to-treat analyses; the non-inferiority margin was 0·63.
Table 2: Immune responses by vaccine schedule at 28 days post boost dose (56 days post prime) in the 28-day prime-boost interval study groups
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oversight of all adverse events in real time. The trial is 
registered with ISRCTN, 69254139.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report.
Results
Between Feb 11 and Feb 26, 2021, 975 participants were 
screened at eight study sites across England, among 
whom 830 were enrolled in the study and randomised. 
463 participants were randomly assigned to the four 
groups with a 28-day prime-boost interval reported in 
this study, including 100 participants enrolled into the 
immunology cohort. The mean age of participants was 
57·8 years (SD 4·7), with 212 (46%) female participants 
and 117 (25%) from ethnic minorities. Baseline 
characteristics were well balanced across the four groups 
in both the general and immunology cohorts (table 1). At 
baseline, 20 (4%) participants were positive for anti-
nucleocapsid IgG (cutoff index ≥1·0), evenly distributed 
(Figure 2 continues on next page)
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across groups. 432 participants were included in the 
modified intention-to-treat analysis and 426 were 
included in the per-protocol analysis (figure 1).
Among participants primed with ChAd, the geometric 
mean concentration of SARS-CoV-2 anti-spike IgG at 
28 days post boost vaccination was 1392 ELU/mL 
(95% CI 1188 to 1630) in the homologous vaccine 
schedule group (ChAd/ChAd) and 12 906 ELU/mL 
(11 404 to 14 604) in the heterologous group (ChAd/BNT), 
with a GMR of 9·2 (one-sided 97·5% CI 7·5 to ∞) 
between heterologous and homologous groups in the 
per-protocol analysis (table 2). The lower limit of the 
one-sided 97·5% CI of the GMR was greater than the 
margin of 0·63, indicating non-inferiority of ChAd/BNT 
compared with ChAd/ChAd. Similar SARS-CoV-2 anti-
spike IgG concentrations were observed in the modified 
intention-to-treat analysis, with a GMR of 9·3 (two-sided 
95% CI 7·7 to 11·4). The GMR of MNA NT50 between the 
heterologous and homologous groups was 6·4 (two-
sided 95% CI 5·2 to 7·8) and the GMR of PNA NT50 
was 8·5 (6·5 to 11·0) in the modified intention-to-treat 
analysis. Cellular responses by T-cell ELISpot were 
greater for ChAd/BNT than ChAd/ChAd, with a GMR 
of 3·9 (2·9 to 5·3; table 2). These results indicate that 
the ChAd/BNT schedule was statistically superior to the 
ChAd/ChAd schedule in terms of the SARS-CoV-2 anti-
spike IgG, MNA NT50, PNA NT50, and cellular responses.
Among participants primed with BNT, the geometric 
mean concentration of SARS-CoV-2 anti-spike IgG at 
28 days post boost vaccination was 14 080 ELU/mL 
(95% CI 12 491 to 15 871) in the homologous group 
(BNT/BNT) and 7133 ELU/mL (6415 to 7932) in the 
heterologous group (BNT/ChAd), with a GMR of 0·51 
(one-sided 97·5% CI 0·43 to ∞) in the per-protocol 
analysis (table 2). The study therefore failed to show 
non-inferiority of BNT/ChAd compared with BNT/BNT. 
Figure 2: Subgroup analyses for immune responses by vaccine schedule at 28 days post boost dose in the 28-day boost study groups
GMRs were adjusted for randomisation stratification variables, including study site and cohort. Two-sided 95% CIs are presented. BNT=BNT162b2 vaccine, 
Pfizer–BioNTech. ChAd=ChAdOx1 nCoV-19 vaccine, AstraZeneca. ELU=ELISA laboratory units. GMR=geometric mean ratio. NT50=50% neutralising antibody titre. 
PBMC=peripheral blood mononuclear cell. SFC=spot-forming units.
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In addition, BNT/ChAd was statistically inferior for 
both SARS-CoV-2 anti-spike IgG (GMR 0·51, 95% CI 
0·44 to 0·60) and PNA NT50 (0·67, 0·51 to 0·88) compared 
with BNT/BNT in modified intention-to-treat analyses. 
The geometric mean SFC frequency (T-cell ELISpot) was 
higher in the heterologous group compared with the 
Figure 3: Correlations between immune responses by vaccine schedule
Correlations at 28 days post boost dose were analysed between SARS-CoV-2 anti-spike IgG and pseudotype virus neutralising antibodies (A), between SARS-CoV-2 
anti-spike IgG and live virus neutralising antibodies (B), between pseudotype virus neutralising antibodies and cellular response by IFNγ ELISpot (C), between live 
virus neutralising antibodies and cellular response by IFNγ ELISpot (D), and between SARS-CoV-2 anti-spike IgG and cellular response by IFNγ ELISpot (E). 
The correlation between SARS-CoV-2 anti-spike IgG and cellular response by IFNγ ELISpot was also analysed at 28 days post prime dose (F). Ellipses show the 
95% CIs for different vaccine schedules, assuming multivariate normal distributions. Pearson correlation coefficients (95% CIs) are presented for each vaccine 
schedule. BNT=BNT162b2 vaccine, Pfizer–BioNTech. ChAd=ChAdOx1 nCoV-19 vaccine, AstraZeneca. ELU=ELISA laboratory units. NT50=50% neutralising antibody 
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R=0·69 (0·57 to 0·78)
R=0·61 (0·47 to 0·72)
R=0·67 (0·54 to 0·76)
R=0·69 (0·57 to 0·78)
R=0·70 (0·58 to 0·79)
R=0·76 (0·67 to 0·83)
R=0·06 (−0·14 to 0·25)
R=0·15 (−0·04 to 0·34)
R=0·10 (−0·09 to 0·29)
R=0·18 (−0·02 to 0·36)
R=0·21 (0·01 to 0·40)
R=0·14 (−0·05 to 0·33)
R=0·13 (−0·07 to 0·31)
R=0·12 (−0·07 to 0·30)
R=0·18 (−0·01 to 0·35)
R=0·36 (0·19 to 0·51)
R=0·14 (−0·06 to 0·32)
R=0·17 (−0·02 to 0·35)
R=0·26 (0·08 to 0·43)
R=0·34 (0·16 to 0·49)
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homologous group, although the difference was not 
statistically significant (GMR 1·2, two-sided 95% CI 
0·87 to 1·7).
Similar patterns of GMRs were found in all subgroup 
analyses, with SARS-CoV-2 anti-spike IgG and PNA 
NT50 consistently higher in the ChAd/BNT group 
compared with the ChAd/ChAd group and higher in the 
BNT/BNT group compared with the BNT/ChAd group 
(figure 2). Strong correlations were found between 
SARS-CoV-2 anti-spike IgG and PNA NT50, and between 
SARS-CoV-2 anti-spike IgG and MNA NT50 at 28 days 
post boost (Pearson correlation coefficients of 0·6–0·7), 
whereas the correlations between humoral responses 
and cellular response were weak (Pearson correlation 
coefficients <0·4) across all vaccine schedules (figure 3).
Across all four schedules in the immunology cohort, an 
increase in SARS-CoV-2 anti-spike IgG was seen from 
day 28 to day 35 (day 7 post boost), contrasting with a lack 
of response at day 7 post prime, suggesting that both 
vaccines induced immunological priming that was 
augmented by either homologous or heterologous boost 
(figure 4, table 3, appendix p 8). No further increase in 
SARS-CoV-2 anti-spike IgG was seen at day 28 post 
boost, suggesting the peak response post boost is likely 
to occur earlier than 28 days. For all schedules except 
ChAd/ChAd, peak T-cell response was observed at 
14 days post boost; no further increase was seen in 
ChAd/ChAd post boost (appendix p 8).
At 14 days post prime, the SARS-CoV-2 anti-spike 
IgG geometric mean concentration was 129 ELU/mL 
(95% CI 83–200) in participants primed with ChAd and 
843 ELU/mL (658–1081) in participants primed with 
BNT (p<0·0001). At 28 days post prime, the concentration 
was 555 ELU/mL (469–657) in participants primed with 
ChAd and 1597 ELU/mL (1407–1812) in participants 
primed with BNT (p<0·0001).
By contrast, ChAd induced significantly higher cellular 
responses at 14 days (p<0·0001) and 28 days (p<0·0001) 
post prime vaccination compared with BNT: geometric 
mean at 14 days was 159 SFC per million PBMCs 
Figure 4: Kinetics of immunogenicity by vaccine schedule
Data presented at days 0, 28, and 56 are based on all participants in the modified intention-to-treat population, whereas data at days 7, 14, 35, and 42 are for the 
modified intention-to-treat population in the immunology cohort only. In parts A and D, data points are medians with IQRs. In parts B and C, the boxplots represent 
the median and 25th and 75th percentiles; the whiskers extend up to the largest value, not greater than 1·5 times the IQR beyond the box (values greater than this 
cutoff are not shown). BNT=BNT162b2 vaccine, Pfizer–BioNTech. ChAd=ChAdOx1 nCoV-19 vaccine, AstraZeneca. ELU=ELISA laboratory units. NT50=50% neutralising 
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(95% CI 119–211) for ChAd versus 32 SFC per million 
PBMCs (22–47) for BNT, and at 28 days was 53 SFC 
per million PBMCs (44–63) for ChAd versus 15 SFC 
per million PBMCs (13–18) for BNT.
When BNT was given as the boost vaccine, similar 
levels of SARS-CoV-2 anti-spike IgG (p=0·44) and PNA 
NT50 (p=0·40) at 28 days post boost were observed among 
participants primed with ChAd (ChAd/BNT) and BNT 
(BNT/BNT). Participants boosted with ChAd after BNT 
prime (BNT/ChAd) had significantly higher SARS-CoV-2 
anti-spike IgG (p<0·0001) and PNA NT50 (p<0·0001) than 
those primed with ChAd (ChAd/ChAd). Homologous 
BNT/BNT immunisation generated higher binding 
antibodies at day 7 (p<0·0001) and day 28 (p<0·0001) 
post boost compared with ChAd/ChAd, with a difference 
also observed in PNA at day 28 post boost (p<0·0001).
In contrast to the lack of further response after a 
homologous second dose of ChAd (figure 4, appendix 
p 8), a significant increase in cellular response was seen 
after a homologous boost with BNT, such that those 
Prime with ChAd Prime with BNT
ChAd/ChAd (n=105) ChAd/BNT (n=108) p value* BNT/BNT (n=110) BNT/ChAd (n=109) p value*
SARS-CoV-2 anti-spike IgG
Day 7†‡
n 21 19 ·· 23 23 ··
Median, ELU/mL 25 (25–25) 25 (25–25) ·· 25 (25–25) 25 (25–25) 0·95
≥50·3 ELU/mL 0 (0%, 0–16) 0 (0%, 0–18) >0·99 2 (9%, 1–28) 2 (9%, 1–28) >0·99
Day 14†
n 21 19 ·· 23 23 ··
Geometric mean, ELU/mL 87 (54–141) 198 (96–408) 0·041 967 (718–1304) 735 (495–1092) 0·39
≥50·3 ELU/mL 14 (67%, 43–85) 16 (84%, 60–97) 0·28 23 (100%, 85–100) 23 (100%, 85–100) >0·99
Day 28
n 105 108 ·· 110 109 ··
Geometric mean, ELU/mL 501 (394–638) 613 (485–776) 0·22 1487 (1233–1795) 1715 (1447–2033) 0·28
≥50·3 ELU/mL 100 (95%, 89–98) 104 (96%, 91–99) 0·75 110 (100%, 97–100) 109 (100%, 97–100) >0·99
Day 35†
n 22 20 ·· 22 24 ··
Geometric mean, ELU/mL 1151 (825–1605) 15 365 (11 764–20 068) <0·0001 17011 (12 446–23 248) 6798 (5060–9133) <0·0001
≥50·3 ELU/mL 22 (100%, 85–100) 20 (100%, 83–100) >0·99 22 (100%, 85–100) 24 (100%, 86–100) >0·99
Cellular response
Day 14†
n 21 19 ·· 23 23 ··
Geometric mean, SFC per million 
PBMCs
182 (133–251) 136 (83–223) 0·21 37 (17–64) 32 (20–51) 0·92
≥4 SFC per million PBMCs 21 (100%, 84–100) 19 (100%, 82–100) >0·99 22 (96%, 78–100) 23 (100%, 85–100) >0·99
≥24 SFC per million PBMCs 21 (100%, 84–100) 17 (89%, 67–99) 0·22 12 (52%, 31–73) 12 (52%, 31–73) >0·99
Day 28
n 103 107 ·· 109 108 ··
Geometric mean, SFC per million 
PBMCs
53 (41–69) 52 (41–66) 0·98 15 (12–18) 16 (13–20) 0·81
≥4 SFC per million PBMCs 101 (98%, 93–100) 107 (100%, 97–100) 0·24 101 (93%, 86–97) 97 (90%, 83–95) 0·48
≥24 SFC per million PBMCs 74 (72%, 62–80) 75 (70%, 60–79) 0·88 34 (31%, 23–41) 35, (32%, 24–42) 0·88
Day 42†
n 22 18 ·· 22 23 ··
Geometric mean, SFC per million 
PBMCs
97 (60–157) 375 (266–528) 0·0022 135 (83–219) 130 (69–243) 0·87
≥4 SFC per million PBMCs 22 (100%, 85–100) 18 (100%, 81–100) >0·99 22 (100%, 85–100) 22 (96%, 78–100) >0·99
≥24 SFC per million PBMCs 19 (86%, 65–97) 18 (100%, 81–100) 0·24 19 (86%, 65–97) 20 (87%, 66–97) >0·99
Data shown are geometric mean (95% CI) for continuous variables, and n (%, 95% CI) for binary variables, unless otherwise indicated; 50·3 ELU/mL was the LLOQ for SARS-CoV-2 anti-spike IgG; 4 SFC per million 
PBMCs was the LLOD and 24 SFC per million PBMCs was the LLOQ for cellular response. ChAd=ChAdOx1 nCoV-19 vaccine, AstraZeneca. BNT=BNT162b2 vaccine, Pfizer–BioNTech. ELU=ELISA laboratory units. 
SFC=spot-forming units. PBMC=peripheral blood mononuclear cell. LLOQ=lower limit of quantification. LLOD=lower limit of detection. *For continuous variables, p values were reported using linear regression 
model adjusting for age, sex, study site, and cohort (where applicable); Fisher’s exact test was used to report p values for binary variables. †Immunology cohort only. ‡Data shown are median (IQR) due to a high 
proportion of censored data; p values were reported using Mann-Whitney U test.
Table 3: Immune responses by vaccine schedule at weekly timepoints post prime dose in the 28-day prime-boost interval study groups
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receiving BNT/BNT had a significantly higher number 
of SARS-CoV-2-specific T cells per million PBMCs 
than ChAd/ChAd (p=0·0028) at 28 days post boost with 
a 28-day interval (figure 4).
Solicited adverse events in the week after immu-
nisation have been reported previously.15 In summary, we 
observed an increase in systemic reactogenicity after 
boost in participants receiving heterologous schedules 
compared with homologous schedules with the same 
prime vaccine. In participants randomly assigned to 
28-day interval groups, there were 316 adverse events in 
178 participants up to 28 days after boost immunisation 
(appendix p 2). No significant difference was observed 
between the vaccine schedules in the proportion of 
participants with at least one adverse event (p=0·89). 
Adverse events of grade 3 or higher are described in the 
appendix (pp 3–4).
Among all participants up to June 6, 2021 (date of data 
lock), there were seven adverse events of special interest, 
of which four were COVID-19 diagnoses (appendix 
pp 5–6). The non-COVID-19 adverse events of special 
interest were not considered to be related to immun-
isation. Three of the cases of COVID-19 diagnosis were 
within 7 days of prime immunisation; one was 54 days 
after prime immu nisation, and the individual had not 
received their planned 28-day boost due to travel 
(appendix p 6). There were four serious adverse events 
across all groups in the study up to the data lock, none of 
which were considered to be related to immunisation 
(appendix p 7).
Discussion
Our findings show that all four schedules studied 
induced concentrations of SARS-CoV-2 anti-spike IgG 
concentrations at least as high as those induced after a 
licensed ChAd/ChAd schedule, which is effective in 
preventing symptomatic COVID-19 when administered 
at a 4–12-week prime-boost interval.21 Nevertheless, the 
BNT-containing schedules were more immunogenic 
than the homologous ChAd/ChAd schedule, and none 
of the heterologous schedules generated binding or 
pseudotype virus neutralising antibodies greater than 
those induced by BNT/BNT immunisation. Cellular 
immune responses in the BNT vaccine-containing 
schedules were similarly all at least as high as the 
ChAd/ChAd group, with BNT/ChAd showing the 
greatest expansion of vaccine-antigen responsive T cells 
in the peripheral circulation at 28 days post boost.
Although the 28-day homologous ChAd/ChAd 
schedule was the least immunogenic of the four 
schedules in our trial, data from a phase 3 randomised 
clinical trial showed this 4-week interval regimen to 
be 76% (95% CI 68–82) efficacious against symptomatic 
disease, and 100% effi cacious against severe disease.22 
This schedule is known to be more immunogenic 
when administered at an 8–12-week schedule.21 When 
deployed in this manner, efficacy against hospitalisation 
has been shown to be 86% (53–96) due to infection with 
the alpha variant (B.1.1.7) and 92% (75–97) with the delta 
variant (B.1.617.2),23 and efficacy against symptomatic 
infection has been shown to be 66% (54–75) with the 
alpha variant and 60% (95% CI 29–77) with the delta 
variant. Given the established associations between 
humoral responses and vaccine efficacy,21 our findings 
indicate that the two heterologous schedules in this 
trial are also likely to be highly effective, and could 
be considered, in some circumstances, for national 
vaccine programmes.
Our results for the ChAd/BNT schedule build on 
preliminary data from a Spanish randomised trial, 
in which 18–60-year-olds received a dose of BNT 
2–3 months after priming with ChAd and showed a 
37-fold increase in SARS-CoV-2 anti-spike IgG at 14 days 
post boost, higher than the 22-fold increase at 7 days 
and 19-fold increase at 28 days post boost in this study.13 
Potential explanations for these differences include the 
longer prime-boost interval, the different sampling 
timepoints, and a younger population in the Spanish 
study.13 Fold increases in the cellular response were, 
however, similar (four-fold in the Spanish study versus 
3·7-fold in this study). Early results from a prospective 
cohort study in Germany, which compared health-care 
workers immunised with BNT/BNT at a 3-week interval 
or ChAd/BNT at an 8–12 week interval, showed similar 
concentrations of binding antibody at 3 weeks post 
boost and higher cellular responses in the ChAd/BNT 
recipients.14 Another German cohort study of 26 par-
ticipants aged 25–46 years receiving a ChAd/BNT 
schedule with an 8-week prime-boost interval reported a 
robust humoral immune response, with a suggestion of 
better retention of neutralising activity against beta 
(B.1.351) and delta variants than that observed in a 
non-randomised cohort receiving BNT/BNT.24
Together with the finding that the T-cell ELISpot 
readouts are similar between schedules, the immuno-
logical data presented here provide reassurance that 
ChAd/BNT and BNT/ChAd are acceptable schedule 
options. However, in contrast with recent non-
randomised and non-blinded studies, we did observe 
increased reactogenicity in the 28-day ChAd/BNT 
schedule,15 compared with ChAd/ChAd. This discrepancy 
could be due to the variation in the prime-boost interval, 
and the forthcoming data from the 84-day prime-boost 
interval participants in this trial will help to delineate this 
difference. Although these mild-to-moderate symptoms 
were transient, they do need to be taken into con-
sideration when deploying the ChAd/BNT schedule, 
especially in individuals younger than the participants 
enrolled in this study, given the reported trend towards 
increased reactogenicity with decreasing age.25,26 
Additional considerations for deployment of mixed 
schedules include potential logistical challenges within 
the health-care infrastructure, as well as the complex 
public communications surrounding this strategy.
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Numerous other randomised heterologous prime-
boost COVID-19 vaccine studies are now underway or 
planned,27 including Com-COV2, which incorporates 
vaccines manufactured by Moderna and Novavax.16 
Crucially, several of these studies include vaccines 
manu factured by CanSinoBIO, Gamaleya Research 
Institute of Epidemiology and Microbiology, and 
Sinovac that are extensively used in low-income and 
middle-income countries, which are potentially more 
likely to rely on mixed schedules. These data on 
heterologous vaccination will also inform third-dose 
booster immun isation programmes, currently being 
considered in preparation for the northern hemisphere 
2021–22 winter28 and being studied in the ongoing 
COV-Boost study.
This study has several limitations. First, as an 
immunogenicity and reactogenicity study, the sample size 
is not adequate to assess vaccine schedule efficacy. 
Although there is evidence that both binding and 
neutralising antibodies correlate well with protection 
against symptomatic disease,21,29,30 the extent to which 
variations in these measures above a specific, unknown, 
threshold affect protection against severe disease is 
unclear. Similarly, we are unable, at this point, to determine 
whether higher antibody concentrations measured at 
28 days post boost immunisation will result in a more 
sustained elevation of vaccine-induced antibodies (as 
might be expected), and this will be evaluated at study 
visits up to 1-year post enrolment. An additional limitation 
is the generalisability of these results to a younger 
population given the age (50–70 years) of participants in 
this trial. Previous randomised trials on homologous 
schedules of viral vector and mRNA vaccines reported 
similar post-boost immunogenicity between younger 
(18–55 years) and older (>55 years) adults, and higher 
reactogenicity in younger cohorts,25,31,32 and there is no 
reason to expect this pattern would be different for the 
heterologous schedules, but it has not been extensively 
shown. Lastly, the data presented here were from 
schedules with a 28-day prime-boost interval, whereas 
the WHO recommended interval for ChAd/ChAd is 
8–12 weeks.33 A longer prime-boost interval is reported 
to result in a higher post-boost SARS-CoV-2 anti-spike 
IgG response for ChAd/ChAd21 and for BNT/BNT,34 but it 
is unknown how lengthening the prime-boost interval 
will affect the heterologous schedules in this study. This 
question will be addressed when the immunogenicity 
data for the schedules including boosting at 84 days 
become available.
In conclusion, our study confirms that the heterologous 
and homologous schedules of ChAd and BNT can induce 
robust immune responses with a 4-week prime boost 
interval. These results support flexibility in deploying 
mRNA and viral vectored vaccines, subject to supply and 
logistical considerations, and emphasise the importance 
of obtaining information on other mixed schedules with 
different prime-boost intervals, especially for vaccines 
For more on the COV-Boost 
study see https://www.
covboost.org.uk
being deployed in low-income and middle-income 
countries.
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